Published in J Urol on April 16, 2011
Randomization of Botox for Stent Pain and Irritative Voiding Symptoms | NCT02078895
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) (2012) 1.04
Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol (2014) 0.91
Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J (2014) 0.80
Current and potential urological applications of botulinum toxin A. Nat Rev Urol (2015) 0.80
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl) (2015) 0.79
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. J Neurotrauma (2016) 0.78
Electroacupuncture at points Baliao and Huiyang (BL35) for post-stroke detrusor overactivity. Neural Regen Res (2013) 0.78
The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA. Urol Ann (2015) 0.78
OnabotulinumtoxinA in the treatment of neurogenic bladder. Biologics (2012) 0.78
Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int J MS Care (2013) 0.78
Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. Can Urol Assoc J (2017) 0.77
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. Int Braz J Urol (2015) 0.77
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J (2014) 0.75
Botulinum toxin A for the Treatment of Overactive Bladder. Toxins (Basel) (2016) 0.75
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J (2017) 0.75
The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol (2013) 0.75
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? World J Nephrol (2016) 0.75
Coining a new term-Urovesicology: advancing towards a mechanistic understanding of bladder symptoms. Transl Androl Urol (2012) 0.75
Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2016) 0.75
Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep (2016) 0.75
Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? Toxins (Basel) (2015) 0.75
Botulinum Toxin Treatment in Multiple Sclerosis-a Review. Curr Treat Options Neurol (2017) 0.75
Use of botulinum toxin for voiding dysfunction. Transl Androl Urol (2017) 0.75
Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World J Urol (2015) 0.75
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. Urol Clin North Am (2017) 0.75
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol (2007) 2.16
Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. J Urol (2010) 2.05
Standardization of terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical assessment group of the International Continence Society. Neurourol Urodyn (2005) 2.04
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol (2007) 2.02
Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol (2006) 2.02
Complications of tension-free vaginal tape surgery: a multi-institutional review. BJU Int (2004) 1.96
Development and external validation of an extended 10-core biopsy nomogram. Eur Urol (2006) 1.90
Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology (2007) 1.83
New Delhi metallo-β-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. CMAJ (2011) 1.73
Is an artificial sphincter the best choice for incontinent boys with Spina Bifida? Review of our long term experience with the AS-800 artificial sphincter. Can J Urol (2002) 1.71
Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int (2007) 1.68
Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol (2007) 1.65
Outcomes in urinary incontinence: reconciling clinical relevance with scientific rigour. Eur Urol (2008) 1.64
The relationship between sexual activity and urinary incontinence in older women. J Am Geriatr Soc (2006) 1.62
Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol (2007) 1.62
Severe soft tissue infection of the thigh after vaginal erosion of transobturator tape for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.61
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol (2010) 1.51
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45
Prospective clinical trial comparing Obtape and DUPS to TVT: one-year safety and efficacy results. Eur Urol (2007) 1.42
Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology (2009) 1.42
Outcomes research: a methodologic review. Eur Urol (2006) 1.39
Ultrasound Evaluation as a Complementary Test in Hidradenitis Suppurativa: Proposal of a Standarized Report. Dermatol Surg (2017) 1.39
A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol (2009) 1.35
A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int (2007) 1.34
Nabilone for the treatment of pain in fibromyalgia. J Pain (2007) 1.30
Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol (2010) 1.26
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int (2011) 1.24
Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn (2008) 1.18
2012 update: guidelines for adult urinary incontinence collaborative consensus document for the canadian urological association. Can Urol Assoc J (2012) 1.18
Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int (2008) 1.18
Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res (2009) 1.17
Transobturator tape compared with tension-free vaginal tape for stress incontinence: a randomized controlled trial. Obstet Gynecol (2009) 1.17
Translating overactive bladder questionnaires in 14 languages. Urology (2006) 1.17
An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int (2005) 1.15
Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol (2006) 1.13
Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol (2008) 1.10
TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther (2009) 1.10
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? Int Urogynecol J (2013) 1.10
Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol (2005) 1.10
Randomized clinical trial comparing suprapubic arch sling (SPARC) and tension-free vaginal tape (TVT): one-year results. Eur Urol (2005) 1.03
Effect of needle size on cancer detection, pain, bleeding and infection in TRUS-guided prostate biopsies: A prospective trial. Can Urol Assoc J (2012) 1.03
The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int (2005) 1.00
Development and external validation of an extended repeat biopsy nomogram. J Urol (2007) 1.00
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int (2006) 0.96
Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC). Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.96
Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol (2007) 0.95
Stability of clinical reasoning assessment results with the Script Concordance test across two different linguistic, cultural and learning environments. Med Teach (2002) 0.94
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur J Cancer (2007) 0.94
Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 0.94
Urological surveillance and management of patients with neurogenic bladder: Results of a survey among practicing urologists in Canada. Can J Urol (2006) 0.94
Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology (2008) 0.94
Age-related changes in prefrontal cortex activity are associated with behavioural deficits in both temporal and spatial context memory retrieval in older adults. Cortex (2009) 0.94
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology (2013) 0.93
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int (2006) 0.93
Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. Eur J Cancer (2006) 0.93
Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec. Can J Urol (2005) 0.93
Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. BJU Int (2009) 0.92
Symptom severity and QOL scales for urinary incontinence. Gastroenterology (2004) 0.92
Early versus delayed repair of vesicouterine fistula. Can Urol Assoc J (2011) 0.92
A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU Int (2007) 0.91
Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther (2011) 0.91
Botulinum toxin injections for paediatric incontinence. Curr Opin Urol (2005) 0.89
The use of synthetic sub-urethral slings in the treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.88
Intraoperative floppy-iris syndrome during cataract surgery in men using alpha-blockers for benign prostatic hypertrophy. J Cataract Refract Surg (2007) 0.88
Post-augmentation bladder perforation during urodynamic investigation. Neurourol Urodyn (2007) 0.87
Childhood trauma and dissociation in first-episode psychosis, chronic schizophrenia and community controls. Psychiatry Res (2013) 0.86
Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int (2007) 0.86
A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil (2012) 0.85
Long-term tensile properties of tension-free vaginal tape, suprapubic arc sling system and urethral sling in an in vivo rat model. J Urol (2007) 0.85
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther (2004) 0.84
Spinal cord injury in Manitoba: a provincial epidemiological study. J Spinal Cord Med (2011) 0.84
Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate (2009) 0.84
Detection of the bladder volume from the neural afferent activities in dogs: experimental results. Neurol Res (2008) 0.83
Normal urodynamic parameters in women: part II--invasive urodynamics. Int Urogynecol J (2011) 0.83
Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology (2004) 0.83
A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil (2010) 0.82
Prevalence and occurrence of stress urinary incontinence in elite women athletes. Can J Urol (2006) 0.82
Impact of personal and ambient-level exposures to nitrogen dioxide and particulate matter on cardiovascular function. Int J Environ Health Res (2011) 0.82
A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol (2006) 0.81
Tissue reactions of the rabbit urinary bladder to cadaveric human fascia lata and polypropylene surgical mesh. Can J Urol (2004) 0.81
Validation of prostate cancer index and SF-12 short forms. Can J Urol (2005) 0.81
Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. J Trauma (2008) 0.81
Effect of the potassium channel opener WAY-133537 on the overactive bladder of spinalized rats. Neurourol Urodyn (2006) 0.81
Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. Can J Urol (2005) 0.81
Therapeutic approach to hormone-refractory prostate cancer. Can J Urol (2006) 0.80
Managing adults with urinary incontinence. Clinical practice guidelines. Can Fam Physician (2002) 0.80
Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. BJU Int (2006) 0.80